LCP-AtorFen Phase II Data to Be Presented at the American Heart Association's 2008 Scientific Sessions in New Orleans, LA, on November 11
H0RSHOLM, Denmark--(BUSINESS WIRE)--Nov. 11, 2008 - LifeCycle Pharma A/S (OMX:LCP) today announced that clinical data from the LCP-AtorFen phase II study will be presented on November 11, 2008, at the American Heart Association's 2008 Scientific Sessions in New Orleans during the Poster Presentation which takes place at 3:00-4:30 PM, Hall A-B1, APS.95.1.
The poster, titled "Atorvastatin/Fenofibrate 40/100 mg Fixed-Dose Combination Tablet (LCP-AtorFen 40/100 mg) Offers Improved Efficacy Over 40mg Atorvastatin and Higher Dose 145 mg Fenofibrate in Patients with Dyslipidemia" will be presented by Michael H. Davidson, Clinical Professor at University of Chicago Pritzker School of Medicine and Executive Medical Director of Radiant Research, on behalf of the LCP-AtorFen Investigator Group. The poster presents positive data on LCP-AtorFen obtained in a 12-week phase 2 study in approximately 220 patients with dyslipidemia as earlier announced by LCP on May 7, 2008. A 52-week safety and efficacy extension is still ongoing.
The five-day conference is being held from November 8 to 12. The American Heart Association's Annual Meeting is the premier meeting for presentation of current patterns in prevention, diagnosis and treatment of cardiovascular disease and stroke, including state-of-the-art cardiovascular research and how it applies to clinical practice. The meeting includes programming in three broad areas of clinical, basic and population science as well as cross-disciplinary translational science and targets a broad audience of physicians, scientists, nurses and health care professionals with a total attendance of more than 27,500.
LCP-AtorFen is the company's proprietary product candidate combining a standard dose atorvastatin (the active ingredient of Lipitor) and the lowest dose of fenofibrate without food effect. LCP-AtorFen is designed to be a powerful and safe treatment of mixed dyslipidemia, addressing three primary cardiovascular risk factors: low density lipoprotein (LDL), high density lipoprotein (HDL) and triglycerides (TG). In North America alone, sales of atorvastatin and fenofibrate were approximately USD 10.8 billion in 2006 (IMS Health; All rights reserved). The company's Phase II clinical program was initiated in July 2007.
About LifeCycle Pharma A/S ("LCP"): LCP is an emerging specialty pharmaceutical company that, through innovative technologies, is able to rapidly develop a portfolio of differentiated products to meet the unique needs of key therapeutic markets and patient populations. This includes products for immunosuppression, specifically organ transplantation, and to combat certain cardiovascular diseases. By using its unique and patented delivery technology, MeltDose(R), LCP is able to develop drugs with enhanced absorption and thereby increased bioavailability. LCP has a cholesterol lowering product, Fenoglide(TM), currently on the US market and a diversified near- and medium-term pipeline, including four product candidates in clinical trials and two in preclinical stages of development. LCP is listed on the OMX Nordic Exchange Copenhagen under the trading symbol (OMX: LCP). For further information, please visit www.lcpharma.com.
LifeCycle Pharma A/S
Dr. Karin Hamberg
Executive Vice President of Research & Development,
Chief Medical Officer
Cell: +45 5115 7722
Posted: November 2008